Paris, France - Although the B-cell depleter rituximab (Rituxan, MabThera; Genentech/IDEC) is not yet marketed for use in the treatment of autoimmune diseases, it is already being used off label in ...

Please provide your email address to receive an email when new articles are posted on . Systemic corticosteroids can lead to CD4 lymphopenia and lower IgG levels. Rituximab therapy can lead to ...

Significant uptake of rituximab biosimilars in Medicare and Medicaid occurred within the first 4 years of marketing in the US. Objectives: This study evaluated the uptake and costs of 3 biosimilars ...

This open-label phase I study enrolled patients 18 years or older with newly diagnosed DLBCL. The first cohort (n = 6) received intravenous rituximab plus CHOP. This cohort received sqR for subsequent ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Severe acute COVID-19 infection, as well as glucocorticoid and rituximab use, increase the risk for ...